Références
Bang Y, Kwak EL, Shaw AT, et al. (2010) Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 28:18s, 2010 (suppl; abstr 3)
Besse B, Vignot S, Soria JC (2010) Lung cancer: an update in 2010. Bull Cancer 97: 161–9
Durand JP, Madelaine I, Scotte F (2009) Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting. Bull Cancer 96: 951–60
Lee YJ, Cho BC, Jee SH, et al. (2010) Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. J Clin Oncol 28: 487–92
Maemondo M, Inoue A, Kobayashi K, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380–8
Mok TS, Wu YL, Thongprasert S, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947–57
Rosell R, Moran T, Queralt C, et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958–67
Sandler A, Gray R, Perry MC, et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542–50
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Rodrigues, M., Routier, E. & Soria, JC. Soins spécifiques, soins de support — même combat !. Oncologie 12, 555–557 (2010). https://doi.org/10.1007/s10269-010-1936-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-010-1936-1